Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05587127

Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia

Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder (ARFID) with weight loss.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The purpose of this study is to conduct a randomized controlled trial (RCT) of a cognitive-behavioral treatment (CBT) compared to usual care as the control with adults with functional dyspepsia who also meet criteria for avoidant/restrictive food intake disorder (ARFID). Participants randomized into the CBT group will receive eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom while the usual care group will be allowed to continue with treatment they are already receiving at the time of randomization. Participants in the usual care group will be offered CBT after study participation. We will determine the feasibility and acceptability of the CBT and explore changes in clinical outcomes and preliminary mechanisms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age at least 18 years at screening visit
  • Rome IV Functional Dyspepsia post-prandial distress type (with or without epigastric pain syndrome)
  • Negative upper endoscopy or upper radiographic GI series to rule out structural/organic cause for FD
  • Avoidant/Restrictive Food Intake Disorder (ARFID) diagnosis (by the Structured Clinical Interview for DSM-5; SCID-5 at Screening visit)
  • ≥5% weight loss from weight after functional dyspepsia symptom onset (at Screening visit)
  • Stable for outpatient care (based on the American Psychiatric Association Practice Guideline for the Treatment of Patients with Eating Disorders)
  • No previous history of CBT for functional dyspepsia or ARFID
  • Computer/internet webcam access
  • Fluency in English
  • Stable dose for 30 days if on any medication

Exclusion criteria

  • Inability to provide informed consent
  • Presence of other conditions that could explain the patient's symptoms by chart:

Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT) Active H.pylori infection (by CLO test or stool antigen test) Active inflammatory bowel disease Eosinophilic gastroenteritis or eosinophilic esophagitis Acute renal failure Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis Acute liver failure Any acute gastrointestinal process Any plausible structural or metabolic causes Heartburn as predominant symptom History of peptic ulcer

  • Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)
  • History of gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and small or large bowel resection)
  • History of any serious medical condition (e.g., cancer)
  • Use of narcotic analgesics greater than three days per week
  • Current pregnancy or breastfeeding within the last 8 weeks
  • Uncontrolled diabetes (indicated by HbA1c ≥7%) by chart
  • Intellectual disability by history
  • Current substance/alcohol use disorder within the past month
  • Current/history of psychosis (by Mini-International Neuropsychiatric Interview (MINI-Screen)
  • Current mania (by Mini-International Neuropsychiatric Interview (MINI-Screen) (defined as any manic episodes within the past 12 months)
  • Active suicidal ideation (by MINI-Screen)
  • Psychiatric disorder that would warrant independent attention (by Mini-International - Neuropsychiatric Interview (MINI-Screen))
  • Current enteral or parenteral feeding
  • Plans to initiate another psychotherapy or pregnancy in the concurrent study period

Treatment and study plan

Cognitive behavioral therapy

Behavioral

Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.

Primary outcomes

  1. Enrollment

    Time frame: Throughout study completion, an average of 3 years

    At the end of the study, we will calculate the percentage of participants who consent to initiate the study from the total who are offered.

  2. Assessment completion

    Time frame: Throughout study completion, an average of 3 years

    At the end of the study, we will calculate the percentage of participants who complete all assessments in each CBT and usual care groups.

  3. Retention

    Time frame: Throughout study completion, an average of 3 years

    At the end of the study, we will calculate the percentage of participants who complete at least 6 of the 8 CBT sessions.

  4. Interventionist Fidelity ratings

    Time frame: Throughout study completion, an average of 3 years

    At the end of the study, we will calculate fidelity, which measures the percentage of sessions that 100% of the CBT content was delivered.

  5. Client Satisfaction

    Time frame: Week 12

    The Client Satisfaction Questionnaire (CSQ) is an 8 item self-report measure that assesses treatment satisfaction. Higher scores indicate greater treatment satisfaction.

Secondary outcomes

  1. Short Form Nepean Dyspepsia Inventory (SF-NDI)

    Time frame: Weeks 0, 6, and 12

    The Short Form Nepean Dyspepsia Inventory (SF-NDI) includes a 15 item symptoms checklist to assess functional dyspepsia symptom severity. It also includes 10 items scored on a 5-point Likert scale measuring functional dyspepsia-related quality of life; subscales include interference with daily activities, knowledge/control, tension, work/study, and eating/drinking.

Study contacts

Contact information is provided by the study sponsor or research team.

Blythe Peterson, BS

CONTACT

[email protected]

617-643-7884

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

A Randomized Controlled Trial of Exposure-Based Cognitive Behavioral Treatment for Avoidant/Restrictive Food Intake in Functional Dyspepsia

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Oct 19, 2022
Registry last updated
Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.